Evotec and Celmatix enter strategic partnership
Evotec SE has expanded its drug discovery customer base with US women’s health specialist Celmatix Inc.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1165 entries already.
Entries by Thomas Gabrielczyk
Researchers unravel how ADEP antibiotics work
/in News/by Thomas GabrielczykGerman researchers have unraveled the mechanism of a ADEPs, a novel class of antibiotics, allowing pharmacological optimisation.
New method allows tracking of HIV
/in News/by Thomas GabrielczykA new method allows real-time-visualisation of how the HI virus spreads between living T helper cells and which molecules it requires for this purpose.
Rottapharm Biotech: POC in osteoarthritis pain
/in News/by Thomas GabrielczykRottapharm Biotech (Monza, Italy) has published detailed results from a clinical Phase II trial of CR4056 in chronic pain from knee osteoarthritis.
Creoptix AG closes CHF8m financing round
/in News/by Thomas GabrielczykSwiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.
AMR: GARDP and Entasis Therapeutics start pivotal study
/in News/by Thomas GabrielczykEntasis Therapeutics Inc (Waltham, USA) and non for profit organisation GARDP (Geneva, Switzerland) have initiated Phase III testing of the novel antibiotic zoliflodacin to treat infections with the WHO priority […]
BASF broadens biotech business by Isobionics acquisition
/in News/by Thomas GabrielczykBASF SE has strengthened its capabilities in recombinant production of natural ingredients by acquiring Dutch Isobionics BV and collaborating with Conagen Inc.
Gut bacterial enzyme keeps inflammation away
/in News/by Thomas GabrielczykAn antimicrobial molecule produced by the human microbiota gut may help fight drug-resistant infections.
Tacalyx GmbH raises 7m in seed funding
/in News/by Thomas GabrielczykGerman Tacalyx GmbH has baged 7m in seed financing to generate antibodies that home in on tumour-antigene specific carbohydrates (TACAs) of glycans.
EMA greenlights new medicines
/in News/by Thomas GabrielczykAt its September meeting, the EMAs CHMP recommended three innovative medicines for EU market approval.